VANI Stock Forecast: Vivani Medical, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Vivani Medical, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 18 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Vivani Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (65): Sales and profits are climbing, and climbing faster than before.
Quality (24): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VANI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VANI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 June 2026 | Lake Street | Initiates | Buy | $4.00 |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Nov 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 Dec 2022 | ThinkEquity | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VANI.
This page is one stock. Monday covers all of them.
VANI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VANI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Vivani Medical, Inc. returned −20.4% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VANI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 5.1×
- EV / EBITDA
- —
Cheaper than 19% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −220.4%
- Return on assets
- −48.5%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vivani Medical, Inc. has a market value of $94.7M and an enterprise value of $86.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$26.3M.
Free cash flow in the twelve months to 30 June 2026: −$26.5M.
Vivani Medical, Inc. employs 42 people.
Data provided by Twelve Data
VANI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VANI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Vivani Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VANI
What is the VANI stock price forecast for 2026-2027?
The median 12-month analyst price target for Vivani Medical, Inc. is $4, with estimates ranging from $3.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VANI stock a buy right now?
Of the 3 analysts covering Vivani Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivani Medical, Inc. 44 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VANI?
As at 18 Nov 2026, Vivani Medical, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (65 of 100).
Will VANI stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $4, and Ticker Nerd's factor model ranks Vivani Medical, Inc. 44 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VANI stock forecast for 2030?
No analyst covering Vivani Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $4 over the next 12 months.
How has VANI stock performed over the past year?
Vivani Medical, Inc. returned -20.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vivani Medical, Inc. do?
Vivani Medical Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company’s current work centers on implant-based therapies designed to deliver medicines steadily over extended periods, with an emphasis on improving medication adherence and tolerability in chronic diseases.
About Vivani Medical, Inc.
Vivani Medical Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company’s current work centers on implant-based therapies designed to deliver medicines steadily over extended periods, with an emphasis on improving medication adherence and tolerability in chronic diseases. Its product pipeline includes GLP-1-based implants under development for obesity, chronic weight management, and type 2 diabetes, reflecting a focus on metabolic health applications. Vivani Medical also operates a neuromodulation segment, broadening its presence in advanced implantable medical technologies. Headquartered in Alameda, California, the company plays a specialized role in the drug-delivery market by addressing challenges associated with frequent oral or injectable dosing through long-duration implant solutions.
CEO Dr. Adam Mendelsohn Ph.D. · 42 employees · United States · https://www.vivani.com